ArchVentures SA
VC Fund
Faro, Portugal
ArchVentures SA is a VC fund in Faro focused on Health Care and Biotechnology. Located in Portugal, ArchVentures SA (ARCH) is a decentralized autonomous corporation (DAC). ARCH was created as a startup holding company which equity is represented by a cryptographic token (Archcoin). The goal is to test new applications of blockchain technology as well as to model an investor-token relationship in a use-case scenario involvinga tangible startup with palpable products and services. To improve equity fungibility, revenue from any of the holding company's products or services is to be used to purchase more tokens from the market, thereby making the holding company's equity token exponentially more valuable with each additional revenue stream.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries ArchVentures SA invests in
Stages ArchVentures SA invests in
Countries ArchVentures SA invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ana Silva
|
|||
Marso SA
|
|||
|
Tiago Silva
|
|||
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 3 (60%)
- Medical 2 (40%)
- Battery 1 (20%)
- Chemical 1 (20%)
Stage
- Series B 3 (60%)
- Series C 1 (20%)
- Series E 1 (20%)
Country
- United States 4 (80%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ana Silva
Financial Advisor
|
Financial Advisor | Total investments: 0 | Find email | |
|
Marso SA
Financial Administration
|
Financial Administration | Total investments: 0 | Find email | |
|
Tiago Silva
Marketing
|
Marketing | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Elephas
|
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodalmicroscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development. | $55M / Series C / Jan 23, 2024 | |
bit.bio
|
Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation. | $103M / Series B / Nov 05, 2021 | |
Singular Genomics
|
Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development andSingular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. | $45.5M / Series B / Jan 01, 2020 | |
908 Devices
|
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need ofanswers, 908 Devices makes personal analyzers, small and simple enough for every workspace. | $17.5M / Series E / Apr 29, 2019 | |
Fast Track
|
Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision:to revolutionize the management of clinical trials. | $15.6M / Series B / Apr 05, 2000 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does ArchVentures SA invest in?
ArchVentures SA invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ArchVentures SA?
Public channels for ArchVentures SA include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ArchVentures SA?
The team at ArchVentures SA includes Ana Silva (Financial Advisor), Marso SA (Financial Administration) and Tiago Silva (Marketing). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
